glp-1 vs glucagon Glucagon-like peptide-1 and glucose-dependent insulinotropic polypeptide analogues in adults with type 2 diabetes mellitus for glycaemic control GLP-1 Receptor Agonists – Peripheral

This article thoroughly traces the developmental milestones of GLP-1 drugs, from their initial discovery to their clinical application, detailing the evolution of diverse GLP-1 medications along with their distinct pharmacological properties

With class action lawsuits filed, these are the alleged side effects of GLP-1 drugs, like Ozempic, Wegovy and Mounjaro.

Recent Findings Retatrutide is the first triple agonist (acting on GLP-1/GIP/glucagon receptors) with published phase 2 data in people with obesity as well as in people with T2D

GLP-1 agonists are a class of drugs that not only treat type 2 diabetes but aid in weight loss